Research note
Tesamorelin has a narrow evidence lane
Why tesamorelin's FDA-labeled use should not be stretched into broad weight-loss or bodybuilding claims.
The claim people usually stretch
Tesamorelin is often pulled into broad conversations about fat loss. The reviewed evidence lane is narrower: FDA labeling supports reducing excess abdominal fat in adults with HIV-associated lipodystrophy.
What Peptide Fact Checks publishes
Peptide Fact Checks separates the labeled context from general wellness, bodybuilding, and ordinary weight-loss claims. A supported claim in one population does not automatically support a wider internet claim.
What this does not cover
This note is educational. It does not provide dosing guidance, protocols, a buying recommendation, or personalized medical advice.